BioCentury | Nov 11, 2020
Product Development

Medicare co-pays for COVID-19 mAbs scrapped, bamlanivimab distribution begins

...serious heart conditions, sickle cell disease or diabetes. Steve Usdin bamlanivimab, LY-CoV555 (LY3819253) Eli Lilly and Co. AbCellera Biologics Inc. U.S. Centers for Disease Control and Prevention chs2020 covid-19 cov19pol covid19 cov19pol...
BioCentury | Oct 1, 2020
Politics, Policy & Law

Offit, McClellan testimonies aim to bolster trust in COVID-19 vaccine developers, review process

...he said.Furthermore, Offit and McClellan both emphasized data safety monitoring boards, FDA’s advisory committee, the Centers for Disease Control and Prevention Advisory...
BioCentury | Sep 16, 2020
Politics, Policy & Law

Vaccine hesitancy: why American values matter

...among the public. Second, decisions by the Centers for Disease Control and Prevention...
BioCentury | Aug 27, 2020
Politics, Policy & Law

CDC reversal on asymptomatic COVID-19 testing, guided by White House task force, prompts backlash

CDC’s flip on asymptomatic COVID-19 testing in exposed individuals has drawn rebuke from at least two state governors, and further jeopardizes public confidence in the agency’s independence. According...
BioCentury | May 27, 2020
Product Development

Non-human primate data sending Junshi, Lilly COVID-19 mAb to clinic

A Chinese Academy of Sciences team has provided evidence showing a mAb against SARS-CoV-2 from Lilly and Junshi is effective in monkeys -- a first for any COVID-19 mAb, according to the researchers -- and...
BioCentury | May 15, 2020
Product Development

Oxford remains on track after saying data back vaccine’s safety, efficacy in monkeys

The University of Oxford, which aims to have its COVID-19 vaccine available for emergency use by September, revealed animal data Thursday supporting its clinical candidate’s safety and protectiveness. Oxford’s Jenner Institute is collaborating with Vaccitech...
BioCentury | May 9, 2020
Product Development

China emerging as a leader in COVID-19 vaccines

China’s biotech sector may still be developing, but the COVID-19 crisis has revealed just how swiftly it can bring new vaccines to the clinic. The country has more COVID-19 vaccine candidates in human testing than...
BioCentury | May 8, 2020
Product Development

Moderna’s Bancel highlights speed, flexibility of mRNA platform as COVID-19 vaccine heads to Phase II

As Moderna readies a Phase II trial of its COVID-19 vaccine just 12 weeks after the virus was sequenced, CEO Stéphane Bancel told BioCentury that the speed of the company mRNA platform could also be...
BioCentury | Apr 29, 2020
Product Development

Pfizer joins front of pack in COVID-19 vaccine race

A COVID-19 vaccine from BioNTech and Pfizer could be available for emergency use by October -- several months ahead of a J&J vaccine and just off the pace of vaccines from Oxford’s Jenner Institute and...
BioCentury | Feb 20, 2020
Politics, Policy & Law

Senate Democrats urge National Security Council to recruit pandemic expert for COVID-19 response

...of NIH’s National Institute of Allergy and Infectious Diseases, and Robert Redfield, director of the Centers for Disease Control and Prevention...
Items per page:
1 - 10 of 369
BioCentury | Nov 11, 2020
Product Development

Medicare co-pays for COVID-19 mAbs scrapped, bamlanivimab distribution begins

...serious heart conditions, sickle cell disease or diabetes. Steve Usdin bamlanivimab, LY-CoV555 (LY3819253) Eli Lilly and Co. AbCellera Biologics Inc. U.S. Centers for Disease Control and Prevention chs2020 covid-19 cov19pol covid19 cov19pol...
BioCentury | Oct 1, 2020
Politics, Policy & Law

Offit, McClellan testimonies aim to bolster trust in COVID-19 vaccine developers, review process

...he said.Furthermore, Offit and McClellan both emphasized data safety monitoring boards, FDA’s advisory committee, the Centers for Disease Control and Prevention Advisory...
BioCentury | Sep 16, 2020
Politics, Policy & Law

Vaccine hesitancy: why American values matter

...among the public. Second, decisions by the Centers for Disease Control and Prevention...
BioCentury | Aug 27, 2020
Politics, Policy & Law

CDC reversal on asymptomatic COVID-19 testing, guided by White House task force, prompts backlash

CDC’s flip on asymptomatic COVID-19 testing in exposed individuals has drawn rebuke from at least two state governors, and further jeopardizes public confidence in the agency’s independence. According...
BioCentury | May 27, 2020
Product Development

Non-human primate data sending Junshi, Lilly COVID-19 mAb to clinic

A Chinese Academy of Sciences team has provided evidence showing a mAb against SARS-CoV-2 from Lilly and Junshi is effective in monkeys -- a first for any COVID-19 mAb, according to the researchers -- and...
BioCentury | May 15, 2020
Product Development

Oxford remains on track after saying data back vaccine’s safety, efficacy in monkeys

The University of Oxford, which aims to have its COVID-19 vaccine available for emergency use by September, revealed animal data Thursday supporting its clinical candidate’s safety and protectiveness. Oxford’s Jenner Institute is collaborating with Vaccitech...
BioCentury | May 9, 2020
Product Development

China emerging as a leader in COVID-19 vaccines

China’s biotech sector may still be developing, but the COVID-19 crisis has revealed just how swiftly it can bring new vaccines to the clinic. The country has more COVID-19 vaccine candidates in human testing than...
BioCentury | May 8, 2020
Product Development

Moderna’s Bancel highlights speed, flexibility of mRNA platform as COVID-19 vaccine heads to Phase II

As Moderna readies a Phase II trial of its COVID-19 vaccine just 12 weeks after the virus was sequenced, CEO Stéphane Bancel told BioCentury that the speed of the company mRNA platform could also be...
BioCentury | Apr 29, 2020
Product Development

Pfizer joins front of pack in COVID-19 vaccine race

A COVID-19 vaccine from BioNTech and Pfizer could be available for emergency use by October -- several months ahead of a J&J vaccine and just off the pace of vaccines from Oxford’s Jenner Institute and...
BioCentury | Feb 20, 2020
Politics, Policy & Law

Senate Democrats urge National Security Council to recruit pandemic expert for COVID-19 response

...of NIH’s National Institute of Allergy and Infectious Diseases, and Robert Redfield, director of the Centers for Disease Control and Prevention...
Items per page:
1 - 10 of 369